과제정보
연구 과제 주관 기관 : Chulalongkorn University
참고문헌
- Amable L (2016). Cisplatin resistance and opportunities for precision medicine. Pharmacol Res, 106, 27-36. https://doi.org/10.1016/j.phrs.2016.01.001
- Kim ES, Tang X, Peterson DR, et al (2014). Copper transporter CTR1 expression and tissue platinum concentration in nonsmall cell lung cancer. Lung Cancer, 85, 88-93. https://doi.org/10.1016/j.lungcan.2014.04.005
- Kommuguri UN, Bodiga S, Sankuru S, et al (2012). Copper deprivation modulates CTR1 and CUP1 expression and enhances cisplatin cytotoxicity in Saccharomyces cerevisiae. J Trace Elem Med Biol, 26, 13-9. https://doi.org/10.1016/j.jtemb.2011.12.001
- Rabik CA, Dolan ME (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 33, 9-23. https://doi.org/10.1016/j.ctrv.2006.09.006
- Rinaldi M, Cauchi C, Gridelli C (2006). First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol, 17, 64-7. https://doi.org/10.1093/annonc/mdj953
- Rose MC, Kostyanovskaya E, Huang RS (2014). Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. Genomics Proteomics Bioinformatics, 12, 198-209. https://doi.org/10.1016/j.gpb.2014.10.003
- Safaei R, Howell SB (2005). Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol, 53, 13-23. https://doi.org/10.1016/j.critrevonc.2004.09.007
- Xu X, Duan L, Zhou B, et al (2012a). Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin Exp Pharmacol Physiol, 39, 786-92. https://doi.org/10.1111/j.1440-1681.2012.05741.x
- Xu X, Ren H, Zhou B, et al (2012b). Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 77, 438-42. https://doi.org/10.1016/j.lungcan.2012.03.023